{"id":"mmx-mesalamine-mesalazine","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Headache"},{"rate":"5-8%","effect":"Abdominal pain"},{"rate":"3-7%","effect":"Diarrhea"},{"rate":"3-5%","effect":"Nausea"},{"rate":"3-5%","effect":"Nasopharyngitis"},{"rate":"2-4%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalamine (5-aminosalicylic acid) acts as a topical anti-inflammatory in the gastrointestinal tract, primarily by inhibiting nuclear factor-kappa B (NF-κB) and reducing production of inflammatory mediators. The MMX formulation uses a multimatrix delivery system that delays drug release until the colon, allowing targeted delivery to the site of inflammation in inflammatory bowel disease.","oneSentence":"MMX mesalamine is an anti-inflammatory agent that reduces inflammation in the colon by inhibiting prostaglandin and leukotriene production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:41.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (induction and maintenance of remission)"},{"name":"Crohn's disease (colonic involvement)"}]},"trialDetails":[{"nctId":"NCT01469637","phase":"PHASE1","title":"Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-07","conditions":"Healthy","enrollment":44},{"nctId":"NCT01130844","phase":"PHASE1","title":"Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-08","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT00545740","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-11-28","conditions":"Diverticulitis","enrollment":590},{"nctId":"NCT00151892","phase":"PHASE3","title":"Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2005-04-08","conditions":"Ulcerative Colitis","enrollment":829},{"nctId":"NCT00446849","phase":"PHASE4","title":"Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Shire","startDate":"2007-05-01","conditions":"Ulcerative Colitis","enrollment":290},{"nctId":"NCT00545103","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-12-06","conditions":"Diverticulitis","enrollment":592},{"nctId":"NCT01418365","phase":"PHASE1","title":"Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-22","conditions":"Healthy","enrollment":30},{"nctId":"NCT01402947","phase":"PHASE1","title":"Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-25","conditions":"Healthy","enrollment":30},{"nctId":"NCT01124149","phase":"PHASE4","title":"Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-29","conditions":"Ulcerative Colitis","enrollment":759},{"nctId":"NCT02093663","phase":"PHASE3","title":"Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2014-12-12","conditions":"Ulcerative Colitis","enrollment":107},{"nctId":"NCT01442688","phase":"PHASE1","title":"Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-07","conditions":"Healthy","enrollment":62},{"nctId":"NCT00679432","phase":"PHASE3","title":"(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT01532648","phase":"PHASE3","title":"Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-01-27","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT00867438","phase":"PHASE2","title":"Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy","status":"COMPLETED","sponsor":"Cosmo Technologies Ltd","startDate":"2007-01","conditions":"Ulcerative Colitis","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lialda","Mezavant","Mezavant XL","Mezavant LP"],"phase":"marketed","status":"active","brandName":"MMX mesalamine/ mesalazine","genericName":"MMX mesalamine/ mesalazine","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MMX mesalamine is a delayed-release formulation of the anti-inflammatory agent mesalamine that targets the colon to reduce inflammation in inflammatory bowel disease. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (induction and maintenance of remission).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}